756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors

• Bin Zhang,
• Marsha Crochiere,
• Anthony W Tolcher,
• Randy Sweis,
• Kartik Sehgal,
• Michael S Gordon,
• Shui He,
• Jason Henry,
• Alexander I Spira,
• Shiraj Sen,
• Sandip P Patel,
• Sondra Smyrnios,
• Dipali Unadkat

Affiliations

Bin Zhang

Beckman Research Institute at City of Hope, Duarte, CA, USA

Marsha Crochiere

13Vigeo Therapeutics, Cambridge, MA, USA

Anthony W Tolcher

13NEXT Oncology, San Antonio, TX, USA

Randy Sweis

8University of Chicago, Chicago, IL, USA

Kartik Sehgal

Monash University, Melbourne, Victoria, Australia

Michael S Gordon

10HonorHealth Thompson Peak Medical Center, Scottsdale, AZ, USA

Shui He

19Replimune, Woburn, USA

Jason Henry

1Sarah Cannon Research Institute, Denver, CO, USA

Alexander I Spira

1Virginia Cancer Specialists, Fairfax, VA, USA

Shiraj Sen

1NEXT Oncology, Irving, TX, USA

Sandip P Patel

8University of California, San Diego, La Jolla, CA, USA

Sondra Smyrnios

9Pyxis Oncology, Boston, MA, USA

Dipali Unadkat

9Pyxis Oncology, Boston, MA, USA